DeciBio News

DeciBio Ventures Invests in Replay’s $55M seed funding round led by KKR & Co. and OMX Ventures

July 25, 2022
Print Friendly and PDF

LOS ANGELES, July 25, 2022 

 

DeciBio Ventures, a venture capital firm investing in and advising precision medicine start-ups, invested in the seed funding round for Replay.  KKR & Co. Inc. and OMX Ventures led this funding round, which totaled $55 million.  Additional participants included ARTISVentures, Lansdowne Partners, SALT, and Axial. 

As part of DeciBio Ventures’ strategy-heavy and supportive VC model, DeciBio Ventures is also providing Replay with ongoing strategic support.

Replay’s portfolio of next-generation genomic medicine technologies aims to solve the key challenges currently limiting clinical progress, including the need for increased payload capacity and off-the-shelf cell therapies that substantially reduce cost of goods, improve production speed, volume and consistency, and expand the potential for genome engineering.

 

Replay’s genomic medicine toolkit comprises several synergistic technology platforms, including:

·      synHSV™ - a high payload capacity HSV vector capable of delivering up to 30x the payload of AAV. synHSV™ facilitates the delivery of large genes, genomic genes, multiple genes, and multiple transcriptional activators and repressors, thereby extending the reach of genomic medicine and opening up the possibility for polygenic therapy

·      uCell™ - a universal, renewable, off-the-shelf, genomically rewritten, hypoimmunogenic iPS cell source for regenerative medicine and cell therapy

·      DropSynth™ - a genome writing platform that enables the rapid, efficient, and low-cost synthesis of libraries of synthetic genes and big DNA

·      LASR™ - an evolutionary inference machine learning algorithm that facilitates the extensive rewriting of proteins to optimize functionality

Replay’s innovative corporate structure separates technology development from therapeutic product development within disease area-specific product companies. Each product company is co-founded by seasoned entrepreneurs in conjunction with international thought leaders in each therapeutic area. To date, Replay has established four synHSV™ gene therapy product companies, aimed at bringing big DNA therapies to monogenic diseases affecting the skin, eye, brain and muscle, and an enzyme writing product company using LASR™ and DropSynth™ to optimize enzyme functionality.

Adrian Woolfson, Executive Chairman,President, and Co-founder of Replay, commented: “We are delighted to have the opportunity to work closely with Decibio, whose strategic insights have proved to be invaluable.” Lachlan MacKinnon, Chief Executive Officer, andCo-founder of Replay, added: “DeciBio is a recognized leading consulting firm in precision medicine. In addition to their consulting expertise, they have access to a broad set of proprietary datasets that we use for our strategic planning. They are extremely well connected within the industry, and we are excited to access their network of experts.”

Beyond Replay’s advanced technologies, DeciBioVentures was drawn to Replay’s uniquely seasoned management team, founders, andBoard members.  Stephane Budel, a co-founder of DeciBio Ventures andDeciBio Consulting, highlighted: “We are excited about our investment inReplay, as we are bullish on the gene and cell therapy space, and on Replay’s underlying IP and technology. In addition, it is rare to run across a start-up management team that is so seasoned across industry, start-ups, and academia.  For example, Replay’s President was EVP at Sangamo Therapeutics, Chief Medical Officer at Nouscom, a Global Clinical Leader atPfizer, and Global Medical Lead at Bristol Myers Squibb.  And, the CEO was a member of the founding team at Oxford Sciences Enterprises (formerly OSI) and a founding investor in Base Genomics, ONI, and OMass Therapeutics. Other co-founders include leading academics in the fields of virology and synthetic biology at top institutions such as Harvard and MIT, with experience inventing ground-breaking technologies – including one of Replay’s technologies – and founding other entities.” 

Replay is headquartered in San Diego, CA andLondon, UK. Additional information is available on its website at www.replay.bio. 

 

About DeciBio 

 DeciBio Ventures is an affiliate of DeciBioConsulting (www.decibio.com), a leading strategy consulting, market intelligence, and SaaS firm dedicated to accelerating the adoption and impact of technologies enabling precision medicine. 

Headquartered in Los Angeles, California,DeciBio Consulting serves a global base of clients and customers, ranging from startups to Fortune 500 healthcare corporations. DeciBio offers advisory services for growth planning, market and opportunity assessment, product and portfolio strategy, voice-of-customer feedback, technology assessment, and commercial due diligence.

DeciBio Ventures was founded in 2021. DeciBio Ventures is a venture capital and value investing firm that invests in precision medicine start-ups and supports its investments by providing ongoing strategic support from industry-leading consultants. 

 

Contact

Carl Schoellhammer

Ventures@DeciBio.com

310.451.4510

Authors
DeciBio Consulting
Related Insights

Precision Medicine is evolving at a rapid pace

Discover how we can help

Contact Us
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.